


CURRICULUM VITAE

| | |
|---|-----------------------|
| Name: | |
| Professor Stephen O'Brien | |
| Present appointment: <i>(Job title, department, and organisation.)</i> | |
| Professor of Haematology at Newcastle University and Consultant Haematologist at the Newcastle Hospitals NHS Foundation Trust. | |
| Address: <i>(Full work address.)</i> | |
| Northern Institute for Cancer Research, International Centre for Life, Newcastle University NE1 4EP | |
| Telephone number: | Email address: |
| 0191 241 8882 | s.g.o'brien@ncl.ac.uk |
| Qualifications: | |
| BSc (Hons) Pathology University of Manchester July 1985 MB ChB University of Manchester July 1987 FRCP (UK) Royal College of Physicians November 1990 MRCPATH Royal College of Pathologists March 1997 PhD Imperial College, University of London May 1998 | |
| Professional registration: <i>(Name of body, registration number and date of registration.)</i> | |
| GMC registration no. 3240090 JCHMT accreditation 17th June 1997 | |
| Previous and other appointments: <i>(Include previous appointments in the last 5 years and other current appointments.)</i> | |
| Undertake NHS service work for 6 sessions per week as a Consultant Haematologist; most clinical workload involves patients with CML from the northern region and beyond. Clinical trials of Imatinib Mesylate in CML and other Ph-positive leukaemias and clinical trials of Imatinib in combination with other agents. Clinical trials of novel signal transduction inhibitors e.g. farnesyl transferase inhibitors, abl/src kinase inhibitors. Developing pharmacogenomic/pharmacoproteomic approaches to predict response to therapy. Pharmacokinetic studies in liaison with Northern Institute of Cancer Research. Monitoring of minimal residual disease in CML patients treated with Imatinib. Using novel technologies such as dHPLC and Sequenom to evaluate Imatinib resistance mechanisms. Development of web-based applications for clinical trial project management. | |
| Research experience: <i>(Summary of research experience, including the extent of your involvement. Refer to any specific clinical or research experience relevant to the current application.)</i> | |
| Treated the first UK patients to receive imatinib in September 1999, and continues to be closely involved with ongoing trials with this agent as well as the newer Tyrosine Kinase Inhibitors. Chief Investigator for the National Cancer Research Network's SPIRIT trials in chronic myeloid leukaemia (www.spirit-cml.org) involving about 1,000 patients in 150 UK hospitals. Member of the European Leukaemia Network, NCRI Haem Onc CSG member of NICE Technology Appraisal Committee C. | |
| Research training: <i>(Details of any relevant training in the design or conduct of research, for example in the Clinical Trials Regulations, Good Clinical Practice, consent or other training appropriate to non-clinical research. Give the date of the training.)</i> | |
| GCP – 27.09.2016 | |
| Relevant publications: <i>(Give references to all publications in the last two years plus other publications relevant to the current application.)</i> | |
| Citations: http://scholar.google.co.uk/citations?user=YqusOX0AAAAJ&hl=e | |
| Signature: | Date: |
|  | 7 March 2017 |